TY - JOUR
T1 - Targeting cancer with mRNA–lipid nanoparticles
T2 - key considerations and future prospects
AU - Kon, Edo
AU - Ad-El, Nitay
AU - Hazan-Halevy, Inbal
AU - Stotsky-Oterin, Lior
AU - Peer, Dan
N1 - Funding Information:
E.K. is the recipient of a fellowship from the Yoran Institute for Human Genome Research. D.P. receives funding support from the European Research Council (advanced grant 101055029), The EXPERT project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 825828, ISF grant 2012/20, the Innovation Authority in Israel (Kamin-Corona), and the Shmunis Family Foundation.
Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2023/11
Y1 - 2023/11
N2 - Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an ongoing research area that started before these versatile nanoparticles were successfully used as COVID-19 vaccines. Currently, efforts are underway to harness this platform for oncology therapeutics, mainly focusing on cancer vaccines targeting multiple neoantigens or direct intratumoural injections of mRNA–LNPs encoding pro-inflammatory cytokines. In this Review, we describe the opportunities of using mRNA–LNPs in oncology applications and discuss the challenges for successfully translating the findings of preclinical studies of these nanoparticles into the clinic. We critically appraise the potential of various mRNA–LNP targeting and delivery strategies, considering physiological, technological and manufacturing challenges. We explore these approaches in the context of the potential clinical applications best suited to each approach and highlight the obstacles that currently need to be addressed to achieve these applications. Finally, we provide insights from preclinical and clinical studies that are leading to this powerful platform being considered the next frontier in oncology treatment.
AB - Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an ongoing research area that started before these versatile nanoparticles were successfully used as COVID-19 vaccines. Currently, efforts are underway to harness this platform for oncology therapeutics, mainly focusing on cancer vaccines targeting multiple neoantigens or direct intratumoural injections of mRNA–LNPs encoding pro-inflammatory cytokines. In this Review, we describe the opportunities of using mRNA–LNPs in oncology applications and discuss the challenges for successfully translating the findings of preclinical studies of these nanoparticles into the clinic. We critically appraise the potential of various mRNA–LNP targeting and delivery strategies, considering physiological, technological and manufacturing challenges. We explore these approaches in the context of the potential clinical applications best suited to each approach and highlight the obstacles that currently need to be addressed to achieve these applications. Finally, we provide insights from preclinical and clinical studies that are leading to this powerful platform being considered the next frontier in oncology treatment.
KW - Humans
KW - COVID-19 Vaccines
KW - COVID-19
KW - Neoplasms/genetics
KW - Nanoparticles
KW - RNA, Messenger/genetics
UR - http://www.scopus.com/inward/record.url?scp=85168084748&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85168084748&partnerID=8YFLogxK
U2 - 10.1038/s41571-023-00811-9
DO - 10.1038/s41571-023-00811-9
M3 - Review article
C2 - 37587254
AN - SCOPUS:85168084748
SN - 1759-4774
VL - 20
SP - 739
EP - 754
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 11
ER -